Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
JIB
GLOBETECH PUBLISHING

New Drug Combinations Block Kidney Cancer in Culture and Mouse Models

By BiotechDaily International staff writers
Posted on 20 May 2013
Image: Senior author Dr. John Copland (Photo courtesy of the Mayo Clinic).
Image: Senior author Dr. John Copland (Photo courtesy of the Mayo Clinic).
Drugs that block the activity of the enzyme Stearoyl-CoA desaturase-1 (SCD1) repress the growth of kidney cancer cells in culture and in mouse models of the disease.

SCD1, which is overexpressed in most kidney cancer samples, is a key enzyme in fatty acid metabolism responsible for forming a double bond in Stearoyl-CoA. This is the way that the monounsaturated fatty acid oleic acid is produced from the saturated fatty acid stearic acid. The ratio of stearic acid to oleic acid has been implicated in the regulation of cell growth and differentiation through effects on cell membrane fluidity and signal transduction.

Investigators at the Mayo Clinic (Jacksonville, FL, USA) worked with a drug that had been designed to block the activity of SCD1 in clear cell renal cell carcinoma (ccRCC), which accounts for almost 85% of kidney cancer cases in the United States.

The investigators examined patient normal and ccRCC tissue samples and cell lines for SCD1 expression. Genetic knockdown models and targeted inhibition of SCD1 through the use of the drug A939572 were analyzed for growth, apoptosis, and alterations in gene expression using gene array analysis. Models of combined therapy using A939572 and the tyrosine kinase inhibitors (TKI) sunitinib and pazopanib, and the mTOR inhibitor temsirolimus were evaluated.

Results published in the May 1, 2013, issue of the journal Clinical Cancer Research revealed increased SCD1 expression in all stages of ccRCC. Both genetic knockdown and pharmacologic inhibition of SCD1 decreased tumor cell proliferation and induced apoptosis in vitro and in vivo. Upon gene array, quantitative real-time PCR, and protein analysis of A939572-treated or genetic SCD1 knockdown samples, induction of endoplasmic reticulum stress response signaling was observed, which suggested a mechanistic mechanism for SCD1 activity in ccRCC. Furthermore, application of A939572 (25% inhibition when applied alone) combined with temsirolimus inhibited tumor growth by 60%–70% in vitro and in vivo.

“There is a clear need for new therapies for this common cancer. With very few exceptions, patients inevitably become resistant to all available treatments,” said senior author Dr. John Copland, professor of cancer biology at the Mayo Clinic.

“We found it [A939572] to be incredibly specific to cancer cells in laboratory mice treated with the agent,” said Dr. Copland. “But these are early days in the testing of this agent for cancer. The synergy between the drugs [A939572 and temsirolimus] was very striking, suggestive of significant clinical benefit in patients.”

Related Links:
Mayo Clinic



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Blocking the activity of HSP101 may imprison the malaria parasite inside its protective vacuole within the red blood cell. In the electron micrograph, the malaria parasites appear in blue and uninfected red blood cells are shown in red (Photo courtesy of the [US] National Institute of Allergy and Infectious Diseases).

Heat Shock Protein Plays Critical Role in Malaria Parasite Protein Trafficking

A pair of recent papers described the molecular operators that enable the malaria parasite Plasmodium falciparum to export a large variety of proteins across the parasitophorous vacuolar membrane (PVM)... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: A one-year-old baby sits in a brain scanner, called magnetoencephalography (MEG)—a noninvasive approach to measuring brain activity. The baby listens to speech sounds such as “da” and “ta” played over headphones while researchers record her brain responses (Photo courtesy of the Institute for Learning & Brain Sciences at the University of Washington).

Brain Scanner Shows Infants’ Brains Rehearse Speech Sounds Months Before Their First Words

New research in 7- and 11-month-old infants revealed that speech sounds stimulate brain regions that coordinate and plan motor movements for speech. The new study suggests that babies’ brains begin establishing... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.